sarafloxacin

Sarafloxacin is a synthetic fluoroquinolone antibiotic that was primarily developed for veterinary use, especially in poultry, to treat and control bacterial infections caused by _Escherichia coli_ and _Salmonella_ species[2][7]. It exhibits broad-spectrum antibacterial activity against both gram-positive and gram-negative bacteria, including _Bacteroides_, _Fusobacterium_, _Eubacterium_, _Actinomyces_, _Peptococcus_, and _Pseudomonas aeruginosa_[1][6]. The mechanism of action involves inhibition of bacterial DNA gyrase (topoisomerase II), an enzyme essential for DNA replication; this leads to disruption of DNA synthesis and cell division in susceptible bacteria[1][6]. Sarafloxacin was developed by Abbott Laboratories but was discontinued before receiving approval for human clinical use[3][4].

Other names

sarafloxacin hydrochloride